iiinova — where your digital self keeps evolving

Reposted by Pranav Garimella

Alex Chang, MD @alexchangmd.bsky.social · 28/07/2025

Awesome infographic on genetic testing in ADPKD by Neera Dahl, @pranavgarimella.bsky.social and Fouad Chebib www.kidneynews.org/view/journal...

25711

Reposted by Pranav Garimella

American Journal of Kidney Diseases @ajkd.bsky.social · 02/05/2025

Associations of Urine Biomarkers During Ambulatory Acute Kidney Injury With Subsequent Recovery in Kidney Function: Findings From the SPRINT Study bit.ly/AJKDAscher25 @pranavgarimella.bsky.social

073

Reposted by Pranav Garimella

Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 05/05/2025

Dotunirab - URAT-1 inhibitor which prevents uric acid reabsorption = uricosuric Nice commentary from @pranavgarimella.bsky.social & Amy Li in @kireports.bsky.social www.kireports.org/article/S246... Drugs mostly only available in Japan Department #NephSky #RheumSky

Diagram showing all uric acid lowering therapies MoA

Figure 1 Title: Summary of common urate-lowering therapies and their mechanisms of action, Legend: Allopurinol and febuxostat are xanthine oxidase inhibitors, reducing the rate of uric acid production. Rasburicase and pegloticase are recombinant uricases that promote conversion of uric acid to allantoin, which is readily excreted in the urine. Probenecid is a nonspecific inhibitor of URAT1 to a much greater extent than OAT1, OAT3, and GLUT9 with a net effect of uricosuria. Dotinurad is a specific URAT1 inhibitor, inhibiting proximal tubular reabsorption of uric acid thereby promoting uricosuria. UA: uric acid; GLUT: glucose cotransporter; NPT: sodium-dependent phosphate transport protein; ABCG2: ATP-binding cassette subfamily G; OAT: organic anion transporter; URAT: uric acid transporter.

0154

Pranav Garimella @pranavgarimella.bsky.social · 05/03/2025

Happening now, Drs @hswapnil.medsky.social and @jordybc.bsky.social discuss resistant hypertension during day 3 of the @kidneyfund.bsky.social #KidneyActionWeek Fantastic discussion!

053

Reposted by Pranav Garimella

Alexander Woywodt @pwoywodt.bsky.social · 05/03/2025

Fascinating read on the ever frustrating topic of publication fees: this paper estimates that between 2019 and 2023 researchers and institutions paid a whopping USD $8.968 billion for their findings to be freely accessible and that costs tripled during that time 💰 arxiv.org/abs/2407.16551

arxiv.org

Estimating global article processing charges paid to six publishers for open access between 2019 and 2023

This study presents estimates of the global expenditure on article processing charges (APCs) paid to six publishers for open access between 2019 and 2023. APCs are fees charged for publishing in some ...

034

Reposted by Pranav Garimella

Brian Rifkin @brianrifkin.bsky.social · 04/02/2025

Hey #NephSky anyone ever heard of orthotopic kidney transplant (nephrectomy & transplant combined)? Have a patient with a good match living donor but poor femoral vessel targets due to calcium. Been turned down twice for kidney transplant surgery due to calcified vessels.

174

Pranav Garimella @pranavgarimella.bsky.social · 21/01/2025

Finally, the KDIGO 2025 #ADPKD Guidelines are out. Whats in it? ✅ Genetic screening for persons at risk ✅ Best approach to managing cyst infection ✅ Considerations for treatment with tolvaptan ✅ ADPKD and mental health All this and much more! www.kidney-international.org/article/S008...

154

Pranav Garimella @pranavgarimella.bsky.social · 08/01/2025

I am happy to announce my appointment as @kidneyfund.bsky.social first Chief Medical Officer! I look forward to lending my clinical expertise to help AKF better serve the 1 in 7 Americans living with kidney disease & joining an organization that fights kidney disease on all fronts.

3133